Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kuros BiosciencesCSBTF 77 Equity-to-Asset is 0.63 as of Dec. 2025, which is 26% below its 10-year median of 0.85. GuruFocus rates CSBTF with a GF Score™ of 77/100 and a GF Value™ of $51.44 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 853 Medical Devices & Instruments companies, Kuros Biosciences ranks worse than 51.35% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Kuros Biosciences's Total Stockholders Equity for the quarter that ended in Dec. 2025 was $106.0 Mil. Kuros Biosciences's Total Assets for the quarter that ended in Dec. 2025 was $168.0 Mil.
Therefore, Kuros Biosciences's Equity to Asset Ratio for the quarter that ended in Dec. 2025 was 0.63.
The historical rank and industry rank for Kuros Biosciences's Equity-to-Asset or its related term are showing as below:
CSBTF'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.63 Med: 0.85 Max: 0.9
Current: 0.63
During the past 13 years, the highest Equity to Asset Ratio of Kuros Biosciences was 0.90. The lowest was 0.63. And the median was 0.85.
CSBTF's Equity-to-Asset is ranked worse than 51.35% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: 0.65
vs CSBTF: 0.63
Kuros Biosciences (OTCPK:CSBTF) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Kuros Biosciences Equity-to-Asset Related Terms
Kuros Biosciences Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Kuros Biosciences's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSBTF vs ABT, SYK, MDT: Equity-to-Asset Comparison
For the Medical Devices subindustry, Kuros Biosciences's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kuros Biosciences Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Kuros Biosciences's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Kuros Biosciences's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Kuros Biosciences's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kuros Biosciences (CSBTF) has a Equity-to-Asset of 0.63 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Kuros Biosciences and its competitors. This is 26% below median its historical median of 0.85. Over the past decade, Kuros Biosciences' Equity-to-Asset has ranged from 0.63 to 0.90. According to the industry distribution chart, Kuros Biosciences ranks #438 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 51.3%.
Is Kuros Biosciences' Equity-to-Asset too high?
Kuros Biosciences' current Equity-to-Asset of 0.63 is 26% below median its 10-year median of 0.85. Over the past 10 years, this metric has ranged from a low of 0.63 to a high of 0.90. The Medical Devices & Instruments industry median Equity-to-Asset is 0.65. Kuros Biosciences' value of 0.63 is 3.1% below this industry median. Based on the distribution chart, Kuros Biosciences ranks #438 out of 853 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Kuros Biosciences has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kuros Biosciences' Equity-to-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Kuros Biosciences ranks #438 out of 853 companies for Equity-to-Asset. This places Kuros Biosciences in the lower half of its industry. The industry median Equity-to-Asset is 0.65. Kuros Biosciences' value of 0.63 is 3.1% below this benchmark. Historically, Kuros Biosciences' own Equity-to-Asset has ranged from 0.63 to 0.90 over the past decade. While the company's 10-year median is 0.85 vs. the industry median of 0.65, Kuros Biosciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.65, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kuros Biosciences's current Equity-to-Asset of 0.63 is 3.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Kuros Biosciences and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kuros Biosciences's current Equity-to-Asset is 0.63, which is 26% below median its own 10-year median of 0.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kuros Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Kuros Biosciences (CSBTF) is currently considered Significantly Undervalued. The stock's GF Value™ is $51.44, compared to a current price of $25.57 — trading 50.3% below its estimated fair value. The current Equity-to-Asset is 0.63, which is 26% below median its 10-year median of 0.85 and 3.1% below the Medical Devices & Instruments industry median of 0.65. Kuros Biosciences' overall GF Score™ is 77/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Kuros Biosciences (CSBTF), the current Equity-to-Asset is 0.63 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kuros Biosciences (CSBTF) Overvalued in 2026?
Based on GuruFocus' analysis, Kuros Biosciences stock appears to be undervalued.
The current stock price of $25.57 is trading 50.3% below its estimated GF Value™ of $51.44.
GuruFocus considers Kuros Biosciences to be Significantly Undervalued.
Key valuation signals for CSBTF:
Equity-to-Asset: 0.63 (26% below median its 10-year median of 0.85)
GF Value™: $51.44 vs. price of $25.57 (50.3% below fair value)
Industry Position: 3.1% below the Medical Devices & Instruments median (#438 of 853)
No single metric tells the full story. See the CSBTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kuros Biosciences Ltd is a Swiss-based biotech company, focused on developing and commercializing biologic bone graft technologies for musculoskeletal applications, particularly in spine, trauma, extremities, and oncology. It has two reportable segments: i) Medical Devices: This segment includes products such as MagnetOs and Attrax, which are biphasic calcium phosphate (BCP) bone grafts that mimic the porous, trabecular structure of cancellous bone. ii) Legacy Portfolio: This segment includes all non-core products (including Checkmate licensing) that are outside the Group's primary therapeutic focus. The majority of the company's revenue is derived from the Medical Devices segment. Geographically, it generates the maximum revenue from the United States of America.
77GF Score
Get the complete analysis for CSBTF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSBTF has been successfully added to your 
